EconomyCSL strikes rare disease drug deal worth up to $1.6 billion with Alentis
Australia’s CSL said it had agreed with Switzerland-based Alentis Therapeutics to jointly develop and promote a treatment for rare kidney and liver diseases. The deal could be worth up to $1.6 billion, excluding development funding.
R
Reuters★★☆☆☆2026-10-04 23:05Original
CSL strikes rare disease drug deal worth up to $1.6 billion with Alentis
Economy